Cargando…

Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach

Current formulations of combined oral contraceptives (COC) containing ethinylestradiol (EE) have ≤35 μg due to increased risks of cardiovascular diseases (CVD) with higher doses of EE. Low‐dose formulations however, have resulted in increased incidences of breakthrough bleeding and contraceptive fai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ezuruike, Udoamaka, Humphries, Helen, Dickins, Maurice, Neuhoff, Sibylle, Gardner, Iain, Rowland Yeo, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282492/ https://www.ncbi.nlm.nih.gov/pubmed/29637542 http://dx.doi.org/10.1002/cpt.1085

Ejemplares similares

Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator
por: Ezuruike, Udoamaka, et al.
Publicado: (2022)

Assessment of Potential Herb-Drug Interactions among Nigerian Adults with Type-2 Diabetes
por: Ezuruike, Udoamaka, et al.
Publicado: (2016)

Ethinylestradiol/Chlormadinone Acetate: Dermatological Benefits
por: Guerra-Tapia, Aurora, et al.
Publicado: (2012)

Quantification of Fetal Renal Function Using Fetal Urine Production Rate and Its Reflection on the Amniotic and Fetal Creatinine Levels During Pregnancy
por: Ezuruike, Udoamaka, et al.
Publicado: (2022)

Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women
por: Blode, Hartmut, et al.
Publicado: (2012)

Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator
por: Kilford, Peter J., et al.
Publicado: (2022)

In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition
por: Murata, Yukiko, et al.
Publicado: (2022)

Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling
por: Doki, Kosuke, et al.
Publicado: (2019)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

Addressing drug safety of maternal therapy during breastfeeding using physiologically‐based pharmacokinetic modeling
por: Pan, Xian, et al.
Publicado: (2022)

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates
por: Pan, Xian, et al.
Publicado: (2021)

Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
por: Humphries, Helen, et al.
Publicado: (2021)

An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling
por: Rowland Yeo, Karen, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan
por: Sun, Lei, et al.
Publicado: (2020)

Transcriptomic and Physiological Responses of Chlorella pyrenoidosa during Exposure to 17α-Ethinylestradiol
por: Zhang, Yurui, et al.
Publicado: (2022)

Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
por: Sun, Lei, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study
por: Rowland Yeo, Karen, et al.
Publicado: (2020)

Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations
por: Johnson, Trevor N., et al.
Publicado: (2022)

Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
por: Jones, HM, et al.
Publicado: (2013)

Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer
por: Walsh, Christopher, et al.
Publicado: (2016)

Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study
por: Reif, Stefanie, et al.
Publicado: (2013)

Effects of Selected Nigerian Medicinal Plants on the Viability, Mobility, and Multidrug-Resistant Mechanisms in Liver, Colon, and Skin Cancer Cell Lines
por: AlQathama, Aljawharah, et al.
Publicado: (2020)

Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects
por: Jordy, Andreas B., et al.
Publicado: (2021)

Application of a Physiologically Based Pharmacokinetic Approach to Predict Theophylline Pharmacokinetics Using Virtual Non-Pregnant, Pregnant, Fetal, Breast-Feeding, and Neonatal Populations
por: Abduljalil, Khaled, et al.
Publicado: (2022)

A best practice framework for applying physiologically‐based pharmacokinetic modeling to pediatric drug development
por: Johnson, Trevor N., et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study
por: Rowland Yeo, Karen, et al.
Publicado: (2023)

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam
por: Wiesinger, Herbert, et al.
Publicado: (2020)

Inhibitory effect of ethinylestradiol on coagulation factors in rats
por: Franco-Murillo, Yanira, et al.
Publicado: (2016)

Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders
por: Vázquez, Mercedes Gómez, et al.
Publicado: (2012)

Developmental Exposure to Ethinylestradiol Affects Reproductive Physiology, the GnRH Neuroendocrine Network and Behaviors in Female Mouse
por: Derouiche, Lyes, et al.
Publicado: (2015)

An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch
por: Zhang, Chao, et al.
Publicado: (2017)

Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome
por: Mathur, Ruchi, et al.
Publicado: (2008)

Manganese‐oxidizing bacteria mediate the degradation of 17α‐ethinylestradiol
por: Sabirova, Julia S., et al.
Publicado: (2008)

Protective effect of heme oxygenase induction in ethinylestradiol-induced cholestasis
por: Muchova, Lucie, et al.
Publicado: (2015)

Detecting Traces of 17α-Ethinylestradiol in Complex Water Matrices
por: Zagalo, Paulo M, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women
por: Feldman, Robert A., et al.
Publicado: (2021)

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model
por: Chetty, Manoranjenni, et al.
Publicado: (2015)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates
por: Tan, Ming‐Liang, et al.
Publicado: (2018)

Ethinylestradiol/gestodene: Isolated cortical cerebral venous thrombosis: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pvosjrl1nl49ka46k2nl25htd0